Bioretec Launches Change Negotiations to Boost Production Efficiency

Bioretec Initiates Change Negotiations to Enhance Operational Efficiency

Bioretec Ltd, a pioneering medical device company from Finland, is embarking on a significant step to streamline its operations. In compliance with the Finnish Act on Co-operation within Undertakings, Bioretec has announced the initiation of change negotiations aimed at improving its competitiveness and profitability.

The negotiations are scheduled to commence on June 8, 2026, and are expected to last approximately two weeks. Affected by this negotiation process are 12 employees within the production function in Finland. As part of the ongoing strategy, the company anticipates that employment terms for up to four individuals may be impacted, including potential terminations. The targeted outcome of these negotiations is to realize annual cost savings of about €0.2 million, which is in addition to a previously stated savings goal of €0.4 million introduced during prior negotiations.

This proactive measure comes on the heels of the company's assessment regarding its production investments. It was revealed that the investments made were disproportionate compared to the actual business development achieved. Back in November 2025, Bioretec engaged in a separate round of negotiations focused on production, which led to the termination of one employee and the temporary layoff of five others. Bioretec has concluded that these efforts alone are insufficient to adequately align production capabilities with current business volumes. Thus, the company sees the need for further measures to appropriately adjust its operational cost structure.

Bioretec emphasizes its commitment to keeping its personnel informed throughout the negotiation process, promising a public announcement regarding the outcomes once the negotiations have concluded.

Bioretec: A Leader in Orthopedic Care

Founded in Finland, Bioretec has positioned itself at the forefront of orthopedic innovation, focusing on the development of fully biodegradable implant technologies that promise to revolutionize fracture healing. The company has developed remarkable expertise in creating active implants that enhance bone growth and facilitate effective recovery following orthopedic surgery.

Among its achievements is the RemeOs™ product line, renowned for its high-performance magnesium alloy and hybrid composite materials. These innovative implants are absorbed naturally by the body and promote faster healing processes without the downside of needing a second surgery for removal. Bioretec received U.S. market authorization for the RemeOs line in March 2023, followed by CE mark approval in Europe in January 2025.

In addition, the Activa product line introduces fully bioabsorbable implants crafted from a proprietary self-reinforced PLGA compound, designed for both adult and pediatric applications.

With its groundbreaking approach to orthopedic treatment, focusing on absorption and natural healing, Bioretec continues to push the boundaries of medical technology. The company’s dedication to innovation paves the way for increasingly effective and patient-friendly solutions in the healthcare sector.

For further details about Bioretec and its pioneering products, visit www.bioretec.com.